Hope for women as breast cancer drug prevents relapses
A spokesperson for the charity welcomed as “encouraging” results of clinical trials in Canada which found the drug, Femara, reduced the risk of death by 39% in women who took it, compared with women who took a placebo.
The news will be particularly relevant for women who have completed the standard five years of tamoxifen therapy. Tamoxifen works well in the treatment of oestrogen-receptor tumours, but women can become intolerant to it and are generally advised to come off it after five years.
